^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Prostatac (PSA/IL-2/GM-CSF vaccine)

    i
    Other names: PSA/IL-2/GM-CSF vaccine
    Associations

    News

    Trials
    Company:
    Theralink
    Drug class:
    IL-2 stimulant, GM-CSF agonist, KLKB1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6years
    Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients (clinicaltrials.gov)
    P1a/1b; N=48; Active, not recruiting; Sponsor: OncBioMune Pharmaceuticals; Trial primary completion date: Dec 2017 --> Dec 2018
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    Prostatac (PSA/IL-2/GM-CSF vaccine)